| 1. |
- Faestermann, T, et al.
(författare)
-
Decay studies of N approximate to Z nuclei from Sr-75 to Sn-102
- 2002
-
Ingår i: European Physical Journal A. Hadrons and Nuclei. - : Springer Science and Business Media LLC. - 1434-6001. ; 15:1-2, s. 185-188
-
Tidskriftsartikel (refereegranskat)abstract
- Neutron deficient nuclei near Sn-100 have been produced by fragmentation of a 1 (.) A GeV Sn-112 beam. The fragments were separated, identified and stopped in a highly segmented silicon strip detector stack. This detector measured the total energy of emitted beta(+)-particles. gamma-radiation was measured with surrounding detectors. The half-lives for many nuclides have been determined for the first time and give important information for the following topics: For the heaviest particle-stable odd-odd nuclei Rh-90, Ag-94 and In-98 we observed for the first time fast beta-decays, compatible with superallowed Fermi transitions and confirmed such decays for 78y, 82 Nb and Tc. We have also observed 'long-lived T = 0 states in some of these nuclei. We measured the half-lives of all rp-process waiting-point nuclei from _Zr up to addition we find the proton drip line nucleus Y-77 to decay dominantly via beta-decay, To study the Gamov-Teller strength in the beta-decay near the doubly magic Sn-102 we measured the half-life, beta- and gamma-spectrum of Sn-102. We propose a level scheme for the daughter nuclide In-102 and deduce the Qamov-Teller strength (B-GT = 4.0 +/- 0.6). This is one of the largest values known.
|
|
| 3. |
- Keck, Michaela Kristina, et al.
(författare)
-
Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification
- 2023
-
Ingår i: Acta Neuropathologica. - : Springer Science and Business Media LLC. - 0001-6322 .- 1432-0533. ; 145:1, s. 49-69
-
Tidskriftsartikel (refereegranskat)abstract
- Pediatric central nervous system (CNS) tumors represent the most common cause of cancer-related death in children aged 0–14 years. They differ from their adult counterparts, showing extensive clinical and molecular heterogeneity as well as a challenging histopathological spectrum that often impairs accurate diagnosis. Here, we use DNA methylation-based CNS tumor classification in combination with copy number, RNA-seq, and ChIP-seq analysis to characterize a newly identified CNS tumor type. In addition, we report histology, patient characteristics, and survival data in this tumor type. We describe a biologically distinct pediatric CNS tumor type (n = 31 cases) that is characterized by focal high-level amplification and resultant overexpression of either PLAGL1 or PLAGL2, and an absence of recurrent genetic alterations characteristic of other pediatric CNS tumor types. Both genes act as transcription factors for a regulatory subset of imprinted genes (IGs), components of the Wnt/β-Catenin pathway, and the potential drug targets RET and CYP2W1, which are also specifically overexpressed in this tumor type. A derived PLAGL-specific gene expression signature indicates dysregulation of imprinting control and differentiation/development. These tumors occurred throughout the neuroaxis including the cerebral hemispheres, cerebellum, and brainstem, and were predominantly composed of primitive embryonal-like cells lacking robust expression of markers of glial or neuronal differentiation (e.g., GFAP, OLIG2, and synaptophysin). Tumors with PLAGL1 amplification were typically diagnosed during adolescence (median age 10.5 years), whereas those with PLAGL2 amplification were diagnosed during early childhood (median age 2 years). The 10-year overall survival was 66% for PLAGL1-amplified tumors, 25% for PLAGL2-amplified tumors, 18% for male patients, and 82% for female patients. In summary, we describe a new type of biologically distinct CNS tumor characterized by PLAGL1/2 amplification that occurs predominantly in infants and toddlers (PLAGL2) or adolescents (PLAGL1) which we consider best classified as a CNS embryonal tumor and which is associated with intermediate survival. The cell of origin and optimal treatment strategies remain to be defined.
|
|
